SG11202108140SA - Anti-bag2 antibody and methods of treating cancer - Google Patents
Anti-bag2 antibody and methods of treating cancerInfo
- Publication number
- SG11202108140SA SG11202108140SA SG11202108140SA SG11202108140SA SG11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA SG 11202108140S A SG11202108140S A SG 11202108140SA
- Authority
- SG
- Singapore
- Prior art keywords
- bag2
- antibody
- methods
- treating cancer
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190016347A KR102172541B1 (ko) | 2019-02-12 | 2019-02-12 | Bag2 항체를 이용한 암 진단용 조성물 및 이를 이용한 방법 |
| KR1020190016359A KR102241558B1 (ko) | 2019-02-12 | 2019-02-12 | Bag2 폴리펩티드 또는 이의 단편에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 |
| PCT/IB2020/051136 WO2020165794A1 (en) | 2019-02-12 | 2020-02-12 | Anti-bag2 antibody and methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108140SA true SG11202108140SA (en) | 2021-08-30 |
Family
ID=72044199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108140SA SG11202108140SA (en) | 2019-02-12 | 2020-02-12 | Anti-bag2 antibody and methods of treating cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12122822B2 (https=) |
| EP (2) | EP3938788A4 (https=) |
| JP (4) | JP7706154B2 (https=) |
| CN (2) | CN114269779B (https=) |
| AU (1) | AU2020222326B2 (https=) |
| BR (1) | BR112021015940A2 (https=) |
| CA (1) | CA3129748A1 (https=) |
| MX (1) | MX2021009690A (https=) |
| SG (1) | SG11202108140SA (https=) |
| WO (2) | WO2020165797A1 (https=) |
| ZA (1) | ZA202106551B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021015940A2 (pt) * | 2019-02-12 | 2021-10-05 | Medpacto, Inc. | Anticorpo anti-bag2 e métodos de tratamento de câncer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560537B2 (en) | 2002-09-30 | 2009-07-14 | Ludwig Institute For Cancer Research | Human sarcoma-associated antigens |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| JP2008518629A (ja) | 2004-11-08 | 2008-06-05 | シェーリング コーポレイション | Ｍｄｌ−１の腫瘍との関連およびその方法 |
| US20060159681A1 (en) * | 2004-12-14 | 2006-07-20 | Functional Neuroscience Inc. | Compositions and methods to inhibit cell loss by using inhibitors of BAG |
| EP2142670A1 (en) * | 2007-04-05 | 2010-01-13 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring, and treatment of breast cancer |
| CA2713156A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| US20100204055A1 (en) * | 2008-12-05 | 2010-08-12 | Bonner-Ferraby Phoebe W | Autoantibody detection systems and methods |
| ITMI20131351A1 (it) | 2013-08-07 | 2015-02-08 | Biouniversa Srl | Molecole leganti il recettore di bag3 per uso terapeutico. |
| JP6637290B2 (ja) * | 2015-11-05 | 2020-01-29 | 武 永安 | Ｃｋ１９に特異的なモノクローナル抗体およびこれを産生するハイブリドーマ、癌の検出キット、癌の検出方法および癌の転移の判定方法 |
| EP3364190A1 (en) * | 2017-02-20 | 2018-08-22 | Panka Cancer Research AG | Method of detecting cancer or cancer cells |
| KR102039624B1 (ko) * | 2017-03-03 | 2019-11-01 | 재단법인 차세대융합기술연구원 | BAG2 및 Cathepsin B 상호결합 억제 물질 스크리닝 방법 |
| KR102230314B1 (ko) * | 2017-10-24 | 2021-03-22 | 주식회사 메드팩토 | 혈액으로부터 암을 진단하는 방법 |
| BR112021015940A2 (pt) * | 2019-02-12 | 2021-10-05 | Medpacto, Inc. | Anticorpo anti-bag2 e métodos de tratamento de câncer |
-
2020
- 2020-02-12 BR BR112021015940-1A patent/BR112021015940A2/pt unknown
- 2020-02-12 US US16/758,930 patent/US12122822B2/en active Active
- 2020-02-12 JP JP2021547311A patent/JP7706154B2/ja active Active
- 2020-02-12 US US16/758,934 patent/US12583915B2/en active Active
- 2020-02-12 CN CN202080027907.0A patent/CN114269779B/zh active Active
- 2020-02-12 JP JP2021547308A patent/JP7747268B2/ja active Active
- 2020-02-12 WO PCT/IB2020/051139 patent/WO2020165797A1/en not_active Ceased
- 2020-02-12 SG SG11202108140SA patent/SG11202108140SA/en unknown
- 2020-02-12 EP EP20755277.9A patent/EP3938788A4/en active Pending
- 2020-02-12 MX MX2021009690A patent/MX2021009690A/es unknown
- 2020-02-12 WO PCT/IB2020/051136 patent/WO2020165794A1/en not_active Ceased
- 2020-02-12 EP EP20755764.6A patent/EP3924382A4/en active Pending
- 2020-02-12 AU AU2020222326A patent/AU2020222326B2/en active Active
- 2020-02-12 CA CA3129748A patent/CA3129748A1/en active Pending
- 2020-02-12 CN CN202080028383.7A patent/CN114761803B/zh active Active
-
2021
- 2021-09-07 ZA ZA2021/06551A patent/ZA202106551B/en unknown
-
2024
- 2024-12-17 JP JP2024220504A patent/JP2025071090A/ja active Pending
- 2024-12-26 JP JP2024229717A patent/JP2025071822A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022521706A (ja) | 2022-04-12 |
| AU2020222326B2 (en) | 2026-03-19 |
| JP7747268B2 (ja) | 2025-10-01 |
| JP2025071090A (ja) | 2025-05-02 |
| CN114269779B (zh) | 2025-05-09 |
| EP3938788A4 (en) | 2023-01-04 |
| WO2020165794A1 (en) | 2020-08-20 |
| MX2021009690A (es) | 2021-10-01 |
| JP2022525843A (ja) | 2022-05-20 |
| CA3129748A1 (en) | 2020-08-20 |
| JP7706154B2 (ja) | 2025-07-11 |
| CN114269779A (zh) | 2022-04-01 |
| EP3924382A4 (en) | 2023-01-04 |
| BR112021015940A2 (pt) | 2021-10-05 |
| CN114761803B (zh) | 2025-09-05 |
| ZA202106551B (en) | 2024-12-18 |
| JP2025071822A (ja) | 2025-05-08 |
| US20230183324A1 (en) | 2023-06-15 |
| CN114761803A (zh) | 2022-07-15 |
| EP3938788A1 (en) | 2022-01-19 |
| US20230194534A1 (en) | 2023-06-22 |
| US12583915B2 (en) | 2026-03-24 |
| WO2020165797A1 (en) | 2020-08-20 |
| EP3924382A1 (en) | 2021-12-22 |
| AU2020222326A1 (en) | 2021-08-19 |
| US12122822B2 (en) | 2024-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL313807A (en) | Claudin 18 antibodies and methods for cancer treatment | |
| IL273196A (en) | Claudin 6 antibodies and methods of cancer treatment | |
| ZA202004735B (en) | Anti-pd-1 antibodies and methods of treatment | |
| IL267803A (en) | Methods for treating cancer with anti-tim-3 antibodies | |
| IL267804A (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| IL266990A (en) | Methods for treating cancer using anti-pd-l1 antibodies and antiandrogens | |
| IL277981A (en) | Cancer treatment methods | |
| IL281441B (en) | Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer | |
| SG11202010793UA (en) | Methods of treating cancer | |
| IL281600B2 (en) | Cancer treatment methods | |
| SG11202111672RA (en) | Cancer associated antibody compositions and methods of use | |
| SG11202103589XA (en) | Materials and methods for treating cancer | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| IL289811A (en) | A method for treating cancer | |
| SG11202005296SA (en) | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer | |
| SG11202107017TA (en) | Methods of treating cancer | |
| ZA202105583B (en) | Methods of diagnosing and treating cervical cancer | |
| SG11202108140SA (en) | Anti-bag2 antibody and methods of treating cancer | |
| IL307556A (en) | Cancer treatment methods using antibodies against TIGIT | |
| PL4003533T3 (pl) | Sposoby leczenia raka wieloogniskowego | |
| HK40073192A (en) | Claudin18 antibodies and methods of treating cancer | |
| HK40053388B (en) | Claudin6 antibodies and methods of treating cancer | |
| IL283912B (en) | Methods for treating cancer using the platenoside molecule and its isomers | |
| IL287342A (en) | Cancer associated antibody compositions and methods of use | |
| GB201903012D0 (en) | Antibodies for treatment of cancer and other diseases |